Navigation Links
Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
Date:1/23/2013

http://Non-24.com.

About TasimelteonTasimelteon is a circadian regulator in development for the treatment of Non-24.  Tasimelteon is a melatonin agonist of the human MT1 and MT2 receptors, with greater specificity for MT2.  Tasimelteon's ability to reset the master body clock in the suprachiasmatic nucleus (SCN), located in the hypothalamus, results in the entrainment of the body's melatonin and cortisol rhythms to align to the 24-hour day-night cycle.  Tasimelteon is currently in Phase III development for Non-24 and Phase IIb/III for Major Depressive Disorder (MDD).

Conference Call
Vanda has scheduled a conference call for today, Wednesday, January 23, 2013 at 9 AM ET to discuss the trial results.  Investors can call 1-866-713-8565 (domestic) and 1-617-597-5324 (international) and use passcode 60037962.  A replay of the call will be available beginning Wednesday, January 23, 2013, at 11:00 AM ET and will be accessible until Wednesday, January 30, 2013, at 11:59 PM ET.  The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers.  The access number is 97367748.

The conference call will be broadcast simultaneously on Vanda's website, http://www.vandapharma.com.  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download and install any necessary software.  The call will also be archived on Vanda's website for a period of 30 days, through February 21, 2013.

About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda, please visit http://
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
2. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
3. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
4. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
5. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
6. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
7. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
8. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
9. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
10. Vanda Pharmaceuticals Reports First Quarter 2012 Results
11. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
(Date:3/26/2015)... Cardiologists at Beaumont Hospital, Royal ... implant of a device recently approved by the Food ... The Watchman Left Atrial Appendage Closure implant is an ... reduce the risk of stroke. Atrial fibrillation ... than 5 million Americans. Twenty percent of all strokes ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... BRISBANE, Calif., Sept. 13 InterMune, Inc. (Nasdaq: ... related to the company,s development program for pirfenidone and ... Annual Congress of the European Respiratory Society (ERS), to ... Dan Welch, Chairman, Chief Executive Officer and President of ...
... Sept. 13 /PRNewswire-Asia-FirstCall/ -- ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
Cached Medicine Technology:InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 2InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 3InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 4InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 2Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 3Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 4Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 6Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 7
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
(Date:3/28/2015)... 28, 2015 Purity Products®, a ... announces the release of their revolutionary new weight ... two randomized, double-blind, placebo-controlled clinical studies to be ... hip size. MuffinStop™ is a combination of two ... mangostana, fused together to create one of the ...
(Date:3/27/2015)... 27, 2015 Wellness for Cancer–the first ... criteria for the spa and wellness industry–has certified Hands ... have experienced or are living with cancer. Hands ... 365® Network, will be identified with a special Wellness ... provider of safe, therapeutic services for cancer patients. , ...
(Date:3/27/2015)... First Choice Emergency Room opened ... is located 12665 W Lake Houston Pkwy, Houston, Texas and ... I look forward to delivering the highest quality emergency medical ... Director of First Choice Emergency Room Summerwood. , ... donation to Summer Creek High School at First Choice Emergency ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 On ... EcoLuxe Lounge in the Stardust Penthouse on the ... Durkin, Los Angeles’ leading sustainable product TV and ... this unforgettable day-long event, which featured some of ... ecologically sound products and services. , “We were ...
Breaking Medicine News(10 mins):Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2
... not all , WEDNESDAY, Oct. 17 (HealthDay News) -- There,s ... , That,s the conclusion of Israeli researchers who reviewed three ... to sham insoles or no treatment for back pain prevention. ... 256 people that focused on the use of insoles for ...
... SuperGen Inc.,(Nasdaq: SUPG ), a pharmaceutical ... of therapies for solid tumors and,hematological malignancies, today ... presentations at the AACR-NCI-EORTC International,Conference from Oct. 22-26 ... The poster presentations will focus on data concerning ...
... is Now Supported to Help Advance Research-, ... within the biomedical market for its innovative genomic ... Release 1.3,of SLIM Search. The SLIM Search genomic ... biomedical research and development.,Version 1.3 includes the following ...
... 17 /Xinhua-PRNewswire/ -- Mindray Medical,International Limited (NYSE: MR ... in China, today announced that it will report,its third ... on,November 1, 2007. Mindray,s management will hold an earnings ... Eastern Time (8:00 AM on November,2, 2007 Beijing/Hong Kong ...
... completing its review of safety,and efficacy data currently ... recommended that the pivotal Phase 3 clinical,trial FAME(TM) ... the current protocol, without change. The trial is ... of diabetic macular edema (DME). FAME is ...
... Oct. 17 Mirixa Corporation, a leading,developer ... facilitate,pharmacist-based patient care services, today announced the ... customized for each,participating pharmacy. RxFYI is free ... patient loyalty and generate revenue. "Patients ...
Cached Medicine News:Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 2Health News:SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference 3Health News:Release 1.3 of SLIM Search Now Available 2Health News:Mindray to Report Third Quarter 2007 Financial Results on November 1, 2007 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 3Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 4Health News:Mirixa Debuts RxFYI - a Free Pharmacy-Published Health eNewsletter Building Patient Loyalty and Generating Revenue 2
A stable revision design with extensive sizes...
Severe revision options for the knee and hip...
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: